Weekly Investment Analysts’ Ratings Updates for Akebia Therapeutics (AKBA)

Several brokerages have updated their recommendations and price targets on shares of Akebia Therapeutics (NASDAQ: AKBA) in the last few weeks:

• 8/17/2026 – Akebia Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/7/2026 – Akebia Therapeutics was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $1.00 price target on the stock.
• 8/6/2026 – Akebia Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 8/3/2026 – Akebia Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – Akebia Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/1/2026 – Akebia Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.

Insider Buying and Selling

In other Akebia Therapeutics news, CFO Erik Ostrowski sold 56,019 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $1.11, for a total value of $62,181.09. Following the transaction, the chief financial officer directly owned 616,616 shares in the company, valued at $684,443.76. This represents a 8.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is currently owned by insiders.

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.